Investigation announced for Investors in shares of NeoGenomics, Inc. (NASDAQ: NEO) over possible Securities Laws Violations announced

An investigation was announced concerning potential securities laws violations by NeoGenomics, Inc. in connection with certain financial statements was announced.

Investors who purchased shares of NeoGenomics, Inc. (NASDAQ: NEO), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of NeoGenomics, Inc. (NASDAQ: NEO) concerning whether a series of statements by NeoGenomics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

NeoGenomics, Inc. reported that its annual Total Revenue rose from $408.83 million in 2019 o $444.44 million in 2020, and that its Net Income declined from $8 million in 2019 to $4.17 million in 2020.

On November 4, 2021, NeoGenomics, Inc. reported its third quarter financial results. In addition, NeoGenomics announced a "leadership team transition". NeoGenomics said that its current CFO led the company through multiple acquisitions, financing events, and navigated the company through the financial challenges associated with the COVID-19 global pandemic and will be namad Chief Sustainability and Risk Officer as of January 1, 2022. NeoGenomics said that William Bonello, who currently is NeoGenomics' President of its Informatics Division, will be named CFO as of January 1, 2022.

On March 28, 2022, NeoGenomics, Inc. announced that its Chief Executive Officer "will step down as CEO and member of the Board, effective immediately." NeoGenomics, Inc. also announced that it "expects revenue for Q1 2022 may be below the low end of its prior guidance of $118 - $120 million and EBITDA for Q1 2022 will be below the low end of its prior guidance of $(15) - $(12) million." NeoGenomics disclosed that "[t]he larger than anticipated EBITDA loss was primarily driven by higher than anticipated Clinical Services cost of goods sold" and that it "has withdrawn its 2022 annual financial guidance issued February 23, 2022."

Shares of NeoGenomics, Inc. (NASDAQ: NEO) declined from $47.13 per share on November 1, 2021, to as low as $9.12 per share on May 6, 2022.

Those who purchased shares of NeoGenomics, Inc. (NASDAQ: NEO) have certain options and should contact the Shareholders Foundation.

Contact:
Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.